SCHEDULE: CVI Investments, Heights Capital Disclose 9.9% Bionano Genomics Stake

CVI Investments and Heights Capital Management have disclosed a 9.9% beneficial ownership stake in Bionano Genomics, primarily through warrants.

Summary

• CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., collectively reported beneficial ownership of 1,129,411 shares of Bionano Genomics, Inc. common stock.
• This ownership represents 9.9% of Bionano Genomics, Inc.'s outstanding common stock.
• The reported shares are issuable upon the exercise of warrants.
• Warrant exercise is subject to limitations, preventing beneficial ownership from exceeding 4.99% or 9.99% for different portions of the warrants.
• Bionano Genomics, Inc. had 10,176,000 shares outstanding as of November 5, 2025, as reported in its Form 10-Q filed on November 13, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has taken a substantial stake, albeit through warrants, indicating potential long-term interest in Bionano Genomics. The warrant structure also implies potential future capital for the company.

Positives

• A significant institutional investor, CVI Investments, Inc., through its manager Heights Capital Management, Inc., holds a substantial stake, potentially indicating confidence in Bionano Genomics' long-term prospects.
• The investment is structured via warrants, which could provide future capital to Bionano Genomics upon exercise, if the company's stock performs well.

Negatives

• The investment is primarily through warrants, which can introduce dilution risk for existing shareholders if exercised.
• The 9.9% stake is close to the 10% beneficial ownership threshold, which could trigger additional reporting requirements or scrutiny if increased.

Risks

• Dilution Risk: The exercise of warrants by CVI Investments could dilute the ownership percentage of existing shareholders.
• Market Price Volatility: The value of the warrants and the underlying common stock is subject to market price fluctuations, impacting the investment's profitability.
• Exercise Limitations: The warrants have exercise limitations (4.99% and 9.99% beneficial ownership caps), which could restrict the investor's ability to fully convert their holdings if not managed carefully or if the company's share count changes significantly.

Future Outlook

This filing does not contain specific forward-looking statements or guidance from Bionano Genomics, Inc. It is a disclosure of beneficial ownership by an institutional investor.

Industry Context

StockSavvy.ai notes that institutional investments in biotechnology companies like Bionano Genomics, especially through warrants, are common. Such investments often signal a belief in the long-term potential of the company's technology (e.g., optical genome mapping) but also reflect a desire for structured investment vehicles that manage risk and potential dilution. The 9.9% stake is a significant passive position for an institutional investor.

Comparison to Industry Standards

• A 9.9% stake is a substantial passive institutional holding, often seen as a vote of confidence in a company's technology or market position.
• Compared to other biotech firms, institutional ownership levels vary widely, but a single entity holding nearly 10% is notable, especially when structured with warrants.
• For example, similar-sized stakes are held by institutional investors in companies like Pacific Biosciences of California (PACB) or Oxford Nanopore Technologies (ONT.L), which also operate in the genomics and sequencing space, indicating a strategic interest in the sector's growth.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but also a signal of institutional confidence.
• Company (Bionano Genomics): Potential for future capital infusion upon warrant exercise.

Key Dates

Recommendation

The disclosure of a significant institutional stake, particularly through warrants, suggests a long-term strategic interest in Bionano Genomics. While the warrant structure introduces potential future dilution, it also signals confidence and a potential source of capital. Given this is an ownership disclosure rather than a performance update, a 'hold' recommendation is appropriate, advising investors to monitor the company's operational performance and the eventual exercise of these warrants.

Keywords

Bionano Genomics, BNGO, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Biotechnology, Genomics, SEC Filing